{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:14:02Z","timestamp":1776878042456,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.exphem.2026.105379","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:08:48Z","timestamp":1768262928000},"page":"105379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluation of dual BCL-2\/BCL-XL inhibition in acute myeloid leukemia preclinical models with and without prior venetoclax therapy"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2612-6471","authenticated-orcid":false,"given":"Reecha","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Kingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Saeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2064-2273","authenticated-orcid":false,"given":"Courtney","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105379_bib0001","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105379_bib0003","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105379_bib0004","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105379_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.exphem.2026.105379_bib0006","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2026.105379_bib0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105379_bib0008","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2026.105379_bib0009","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105379_bib0010","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","article-title":"Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105379_bib0002","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105379_bib0011","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/bloodadvances.2024012906","article-title":"Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status","volume":"8","author":"Dolnikova","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2026.105379_bib0012","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, A dual inhibitor of Bcl-2 and BCL-XL, induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2026.105379_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.exphem.2026.105379_bib0014","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-5193(85)80176-4","article-title":"The expected effect of a combination of agents: the general solution","volume":"114","author":"Berenbaum","year":"1985","journal-title":"J Theor Biol"},{"key":"10.1016\/j.exphem.2026.105379_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2024013423","article-title":"Anti-leukemia efficacy of the dual BCL2\/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models","volume":"9","author":"Kannan","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2026.105379_bib0016","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1182\/bloodadvances.2024013194","article-title":"The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL","volume":"8","author":"Wichert","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2026.105379_bib0017","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","article-title":"Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism","volume":"73","author":"Rahmani","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2026.105379_bib0018","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2026.105379_bib0019","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/13543776.2022.2116311","article-title":"Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins","volume":"32","author":"Pal","year":"2022","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.exphem.2026.105379_bib0020","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2026.105379_bib0021","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by Protac 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105379_bib0022","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2015.130351","article-title":"Co-administration of the mTORC1\/TORC2 inhibitor INK128 and the Bcl-2\/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation","volume":"100","author":"Rahmani","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105379_bib0023","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.3390\/ijms24087180","article-title":"Synergistic action of MCL-1 inhibitor with BCL-2\/BCL-XL or MAPK pathway inhibitors enhances acute myeloid leukemia cell apoptosis and differentiation","volume":"24","author":"Opydo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105379_bib0024","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ijms25010484","article-title":"Venetoclax and hypomethylating agent combination in myeloid malignancies: mechanisms of synergy and challenges of resistance","volume":"25","author":"Mishra","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105379_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105379_bib0026","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:31:29Z","timestamp":1773750689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0301472X26000123"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105379","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of dual BCL-2\/BCL-XL inhibition in acute myeloid leukemia preclinical models with and without prior venetoclax therapy","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105379"}}